Calliditas Therapeutics AB (publ) 0A5R.L Stock
Calliditas Therapeutics AB (publ) Price Chart
Calliditas Therapeutics AB (publ) 0A5R.L Financial and Trading Overview
| Calliditas Therapeutics AB (publ) stock price | 115.7 SEK |
| Previous Close | 93.05 SEK |
| Open | 93.55 SEK |
| Bid | 0 SEK x N/A |
| Ask | 0 SEK x N/A |
| Day's Range | 93.45 - 93.55 SEK |
| 52 Week Range | 58.85 - 133.5 SEK |
| Volume | 685 SEK |
| Avg. Volume | 16.82K SEK |
| Market Cap | N/A |
| Beta (5Y Monthly) | 1.353962 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -11.207 SEK |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0A5R.L Valuation Measures
| Enterprise Value | 4.85B SEK |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 8.509378 |
| Enterprise Value/Revenue | 5.136 |
| Enterprise Value/EBITDA | -13.199 |
Trading Information
Calliditas Therapeutics AB (publ) Stock Price History
| Beta (5Y Monthly) | 1.353962 |
| 52-Week Change | 6.29% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 133.5 SEK |
| 52 Week Low | 58.85 SEK |
| 50-Day Moving Average | 113.97 SEK |
| 200-Day Moving Average | 98.58 SEK |
0A5R.L Share Statistics
| Avg. Volume (3 month) | 16.82K SEK |
| Avg. Daily Volume (10-Days) | 18.78K SEK |
| Shares Outstanding | N/A |
| Float | 37.29M |
| Short Ratio | N/A |
| % Held by Insiders | 14.42% |
| % Held by Institutions | 38.90% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -41.58% |
| Operating Margin (ttm) | -39.17% |
| Gross Margin | 97.50% |
| EBITDA Margin | -38.91% |
Management Effectiveness
| Return on Assets (ttm) | -14.76% |
| Return on Equity (ttm) | -53.78% |
Income Statement
| Revenue (ttm) | 944.5M SEK |
| Revenue Per Share (ttm) | 17.71 SEK |
| Quarterly Revenue Growth (yoy) | 284.80% |
| Gross Profit (ttm) | 787.68M SEK |
| EBITDA | -367529248 SEK |
| Net Income Avi to Common (ttm) | -392745984 SEK |
| Diluted EPS (ttm) | -11.207 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.01B SEK |
| Total Cash Per Share (mrq) | 18.89 SEK |
| Total Debt (mrq) | 746.9M SEK |
| Total Debt/Equity (mrq) | 126.72 SEK |
| Current Ratio (mrq) | 3.934 |
| Book Value Per Share (mrq) | 10.982 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -351871008 SEK |
| Levered Free Cash Flow (ttm) | -199020752 SEK |
Profile of Calliditas Therapeutics AB (publ)
| Country | United Kingdom |
| State | N/A |
| City | Stockholm |
| Address | Kungsbron 1, D5 |
| ZIP | 111 22 |
| Phone | 46 84 11 30 05 |
| Website | https://www.calliditas.se |
| Industry | |
| Sector(s) | |
| Full Time Employees | 181 |
Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
Q&A For Calliditas Therapeutics AB (publ) Stock
What is a current 0A5R.L stock price?
Calliditas Therapeutics AB (publ) 0A5R.L stock price today per share is 115.7 SEK.
How to purchase Calliditas Therapeutics AB (publ) stock?
You can buy 0A5R.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Calliditas Therapeutics AB (publ)?
The stock symbol or ticker of Calliditas Therapeutics AB (publ) is 0A5R.L.
How many shares does Calliditas Therapeutics AB (publ) have in circulation?
The max supply of Calliditas Therapeutics AB (publ) shares is 0.
What is Calliditas Therapeutics AB (publ) Price to Earnings Ratio (PE Ratio)?
Calliditas Therapeutics AB (publ) PE Ratio is now.
What was Calliditas Therapeutics AB (publ) earnings per share over the trailing 12 months (TTM)?
Calliditas Therapeutics AB (publ) EPS is -11.207 SEK over the trailing 12 months.